MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH

Key Points

• MSH Capital Advisors acquired 6,242 Guardant Health shares worth approximately $936,000 during the second quarter. Institutional investors collectively own 92.60% of the company, with several other funds also initiating positions.
• Guardant Health insiders sold 546,224 shares valued at approximately $80.4 million over the past 90 days, including substantial sales by Director Medina Manuel Hidalgo and insider Terilyn J. Monroe.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $183.78. The company’s latest quarterly revenue rose 44.3% year over year to $335.0 million, while its loss per share was narrower than expected.

MSH Capital Advisors LLC acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,242 shares of the company's stock, valued at approximately $936,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Lisanti Capital Growth LLC purchased a new stake in Guardant Health during the second quarter worth approximately $1,592,000. Eagle Health Investments LP acquired a new stake in Guardant Health during the second quarter worth approximately $45,112,000. Wealthfront Advisers LLC purchased a new stake in shares of Guardant Health during the 2nd quarter worth approximately $458,000. Alpine Woods Capital Investors LLC acquired a new stake in Guardant Health during the 2nd quarter worth $237,000. Finally, Deutsche Bank AG acquired a new stake in Guardant Health during the 2nd quarter worth $24,385,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 1,700 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total transaction of $279,208.00. Following the sale, the director owned 4,556 shares of the company's stock, valued at approximately $748,277.44. The trade was a 27.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Terilyn J. Monroe sold 46,300 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider owned 22,979 shares in the company, valued at $3,794,292.48. The trade was a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 546,224 shares of company stock worth $80,435,493. 5.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

GH has been the topic of several research reports. Stephens raised their price objective on Guardant Health from $170.00 to $195.00 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Barclays upped their target price on Guardant Health from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. BTIG Research boosted their price objective on Guardant Health from $190.00 to $195.00 and gave the company a "buy" rating in a research note on Friday, July 31st. UBS Group set a $150.00 price objective on Guardant Health in a report on Wednesday, June 24th. Finally, Guggenheim lifted their target price on shares of Guardant Health from $160.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Guardant Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $183.78.

Guardant Health Trading Up 2.0%

Shares of GH opened at $163.34 on Thursday. The stock's 50 day moving average is $152.39 and its two-hundred day moving average is $117.95. Guardant Health, Inc. has a twelve month low of $53.40 and a twelve month high of $176.58. The firm has a market capitalization of $21.92 billion, a PE ratio of -46.80 and a beta of 1.60.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same period in the prior year, the business earned ($0.44) earnings per share. The firm's quarterly revenue was up 44.3% compared to the same quarter last year. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source